title: Natalizumab modulates the humoral response against HERV-Wenv73-88 in a follow-up study of Multiple Sclerosis patients.
abstract: Multiple Sclerosis (MS) is a heterogeneous disorder of the central nervous system (CNS) that begins as an inflammatory autoimmune disorder mediated by auto-reactive lymphocyte followed by microglial activation and chronic degeneration. The etiology of Multiple Sclerosis (MS) is unknown but several data support the hypothesis of possible infectious agents which may act as a trigger for the pathogenic cascade. Human endogenous retrovirus (HERV-W/MSRV), Epstein Barr Virus (EBV) and Mycobacterium avium ss. paratuberculosis (MAP) have been associated to Multiple Sclerosis. In this study, we evaluated the humoral response against different peptides: the human endogenous retrovirus HERV-Wenv73-88, MAP106c121-132 from MAP, EBNA1 400-413 from EBV and the homologous human peptide MBP85-98 in a cohort of MS patients treated with natalizumab. Results showed a statistically significant difference in the response against the HERV-W peptide in MS patients after two years of natalizumab treatment.
authors.affiliation: Dipartimento di Scienze Biomediche, Sezione di Microbiologia, Università di Sassari, Viale San Pietro 43b, 07100 Sassari, Italy.
authors.forename: Giannina
authors.initials: G
authors.lastname: Arru
authors.affiliation: Dipartimento di Scienze Biomediche, Sezione di Microbiologia, Università di Sassari, Viale San Pietro 43b, 07100 Sassari, Italy.
authors.forename: Elisa
authors.initials: E
authors.lastname: Caggiu
authors.affiliation: Dipartimento di Medicina Clinica e Sperimentale, Università di Sassari, Viale San Pietro 43b, 07100 Sassari, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Leoni
authors.affiliation: Dipartimento di Scienze Biomediche, Sezione di Microbiologia, Università di Sassari, Viale San Pietro 43b, 07100 Sassari, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mameli
authors.affiliation: Dipartimento di Medicina Clinica e Sperimentale, Università di Sassari, Viale San Pietro 43b, 07100 Sassari, Italy.
authors.forename: Maura
authors.initials: M
authors.lastname: Pugliatti
authors.affiliation: Dipartimento di Medicina Clinica e Sperimentale, Università di Sassari, Viale San Pietro 43b, 07100 Sassari, Italy.
authors.forename: Gian Pietro
authors.initials: GP
authors.lastname: Sechi
authors.affiliation: Dipartimento di Scienze Biomediche, Sezione di Microbiologia, Università di Sassari, Viale San Pietro 43b, 07100 Sassari, Italy. Electronic address: sechila@uniss.it.
authors.forename: Leonardo A
authors.initials: LA
authors.lastname: Sechi
mesh_terms: D000328:Adult; D000906:Antibodies / Q000097:blood; D016022:Case-Control Studies; D020077:Endogenous Retroviruses / Q000276:immunology*; D019309:Epstein-Barr Virus Nuclear Antigens / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D015686:Gene Products, env / Q000276:immunology; D006801:Humans; D056724:Immunity, Humoral / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D004676:Myelin Basic Protein / Q000276:immunology*; D000069442:Natalizumab / Q000276:immunology* / Q000627:therapeutic use*; D009842:Oligopeptides / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology*; D011257:Pregnancy Proteins / Q000276:immunology; D055815:Young Adult
chemical_list: D000906:Antibodies; D019309:Epstein-Barr Virus Nuclear Antigens; D015686:Gene Products, env; C000610574:MAP106c protein (121-132); D004676:Myelin Basic Protein; D000069442:Natalizumab; D009842:Oligopeptides; D010446:Peptide Fragments; D011257:Pregnancy Proteins; C000610573:myelin basic protein (85-98); C405335:syncytin; C417029:EBV-encoded nuclear antigen 1
keywords: Antibodies; ELISA; Epstein Barr Virus (EBV); HERV-Wenv; Multiple Sclerosis; Mycobacterium avium ss. paratuberculosis (MAP); Natalizumab therapy